Background: This analysis was undertaken to assess the relationship between the dose intensity (DI) of initial chemotherapy and outcome in a large cohort of patients with advanced Hodgkin lymphoma treated in a randomised controlled trial, in which detailed dose data were collected prospectively.
introduction
The introduction of combination chemotherapy has led to a steady improvement in the treatment of patients with advanced Hodgkin lymphoma (HL). Prospective multicentre randomised controlled trials have shown that the anthracycline-containing regimen of doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) is superior to the alkylator-based four-drug regimens such as mechlorethamine, vincristine, procarbazine and prednisolone [1, 2] , while in comparison to more complex multidrug alternating, weekly or hybrid regimens have not shown further benefit from the introduction of more than four drugs [3, 4] . The intensive, escalated BEACOPP (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone) regimen developed by the German Hodgkin Study Group [5] has given results which indicate superiority over ABVD for control of the lymphoma in one trial [6] , and another is still in progress (http://www.cancer.gov/clinicaltrials/EORTC-20012).
At present, however, ABVD chemotherapy remains the regimen of choice in many centres. This choice is based upon the perceived lower toxicity of the ABVD regimen, particularly in avoiding late effects such as infertility and myelodysplasia/ acute leukaemia. However, 30%-40% of patients with advanced HL treated with ABVD will relapse within 5 years [7] , and efforts continue to find strategies which will improve the results for this minority, without imposing an unnecessary burden of toxicity on the whole population. One such approach is to use response-adapted therapy, in which an early assessment of response is used to escalate treatment only for those patients where the initial/very early effect is inadequate and reduce therapy only for those in whom an excellent early response is seen. In doing this, there remains uncertainty as to how intensive the initial treatment needs to be: can an escalation after two cycles compensate for an apparently inadequate response or do all patients require maximally intense treatment initially?
In order to further consider this question, we have analysed the results of different levels of dose intensity (DI) in patients receiving ABVD as part of a large prospective randomised trial.
patients and methods
In the UK Lymphoma Group LY09 trial, 788 eligible adult patients with newly diagnosed advanced HL (stage III-IV, or earlier stage with systemic symptoms, more than three sites of involvement or bulky disease, defined as over one-third of the transthoracic ratio or 10 cm outside the chest) were randomly allocated to treatment with either ABVD or one of two multidrug regimens. The present analysis was conducted using data only from the patients allocated to treatment with ABVD. During treatment, the doses of drugs administered were recorded prospectively for each cycle. Full details have been reported previously [4] .
In summary, all patients allocated to ABVD were planned to have six 28-day cycles of ABVD chemotherapy, with drugs administered on days 1 and 15; this was extended to eight cycles where there was evidence of continuing response after six cycles. Data on drug doses administered were collected on standardised forms for each cycle. Dose modification criteria were based upon the original publication of the ABVD regimen [2] , with a 50% reduction specified for doxorubicin and vinblastine if the total leucocyte count was <3.8 · 10 9 /l on the day of scheduled dosing and a delay if it was <2.5 · 10 9 /l. Growth factor support was recommended if patients experienced a second episode of myelosuppression meeting the criteria for dose delay or reduction. In this case, subsequent treatment was advised with growth factors in every cycle, still following the same criteria for treatment. Radiotherapy was recommended for residual masses or at the sites of prior bulk disease. Patients were recruited from 1998 to 2002.
This analysis includes 380 patients allocated to treatment with ABVD who received at least two cycles of chemotherapy. Data for analysis were frozen on 18 July 2008 with median follow-up of 6.9 years (reverse censoring on death). Figure 1 presents the selection process for this analysis.
Standardised dose administered was calculated as the reported dose given divided by the expected protocol-specified dose. DI (or dose per unit time) was defined as standardised dose divided by standardised time, where standardised time was the observed duration divided by the expected duration, i.e. from day 1 of one cycle to day 1 of the next cycle. The duration of the final cycle of chemotherapy cannot be directly calculated in this way and was estimated as the average duration of all the previous cycles. Standardised dose and DI were calculated cumulatively. Separate summaries were produced for the first two cycles of allocated chemotherapy and for cycles 3 up to 6. Cycles beyond cycle 6 were excluded for the purposes of these analyses. Standardised dose and DI were calculated separately for doxorubicin, bleomycin, dacarbazine and vinblastine; an overall average was also calculated from these data, giving equal weighting to each of the four drugs. The data were divided into three groups for convenience, particularly given the distribution of the data. The cut points chosen were <86%, 86%-97% and >97%. These cut points split the DI data into three approximately equally sized groups and were used also in the previous report of the trial. The same groupings were used for standardised dose for convenience.
Progression-free survival (PFS) and overall survival (OS) were timed from the start of cycle 3 in a landmark approach; PFS event was defined as disease progression at any time or death from any cause. Standard survival analysis methods were employed for the time-to-event data.
results
This analysis includes 380 (47%) patients randomly allocated to the trial. Table 1 presents the baseline characteristics of the patients included. Table 2 shows the breakdown for each of the drugs for standardised dose and DI. As expected, there is more variation in standardised dose than DI. During the first two cycles of treatment, 94 of the 380 patients (25%) received treatment at >97% intended DI averaged across all four drugs, while 140 (37%) received treatment between 86% and 97% and 146 (38%) at <86% ( Table 2 ). The proportion of patients receiving lower initial DI showed some variation between prognostic groups, with slightly more patients of high stage, low performance status and high International Prognostic Score (IPS) falling into the lowest group for DI. Two-thirds of these patients had six cycles of chemotherapy (254 of 380). The majority of dose reductions were in response to low leucocyte counts, most often on day 15 of cycle 1. The dose reductions in vinblastine were slightly greater than those seen for doxorubicin, reflecting dose capping in some centres. The correlation between DI in cycles 1 and 2 and that in the remaining cycles is strong in all cases ( Figure 1 and Table 2 ). A total of 94 (65%) of 146 patients who received <86% of intended DI in cycles 1-2 received a similarly low DI for cycles 3-6, while of those who received >97% intended DI in cycles 1-2, only 21 of 93 (23%) had <86% in cycles 3-6 (data missing for one patient). Poorer average DI in cycles 1-2 was associated with increased reported use of granulocyte colony-stimulating factor (G-CSF) at any time during chemotherapy: 93 of 146 (64%) patients with lower average DI in cycles 1 and 2 reported G-CSF use compared with 19 of 92 (21%) with higher average. This did not apparently reverse the relationship between initial and subsequent DI: only 7 of 146 (5%) patients who received <86% of intended DI in cycles 1-2 went on to receive >97% average DI in cycles 3-6.
Based on 104 reported PFS events, the analysis of PFS showed no good evidence that this was affected by the average Figure 2 depicts the associated Kaplan-Meier graph. Similar results were shown for the univariate analyses of each of the four drugs individually (Table 3 ) and when adjusted for baseline IPS score; these analyses were timed from the start of cycle 3. In order to consider a possible effect from protocol treatment after cycles 1 and 2, a further multivariate analysis was carried out only in those patients who completed six cycles of chemotherapy (n = 333). There was no clear evidence of an impact from either early (cycles 1-2) or late (cycles 3-6) DI on PFS. The adjusted HRs are shown in the final columns of Table 3 ; these analyses were timed from after the end of cycle 6.
There was some evidence of an association between DI in cycles 1-2 and the use of consolidation radiotherapy, with 51% of patients in the highest DI group going on to receive radiotherapy compared with 34% and 38% in the lower DI groups, respectively. We have noted elsewhere [8] that the use of radiotherapy is associated with better outcome in this patient group; despite this, there was no clear evidence that higher DI was associated with better outcome.
Based on 56 deaths, there was no evidence of an effect of average DI in cycles 1 and 2 on OS (HR 0.84, 95% CI 0.59-1.19; P = 0.324).
discussion
There are two potential strategies which might improve the results of treatment of advanced HL. The first would be to intensify initial treatment of those with poor prognosis based on the IPS described by Hasenclever and Diehl [7] . This has been partly tested through the use of myeloablative therapy in first remission in two prospective trials and has not shown an advantage [9, 10] . There is, however, the possibility that intensification within the sub-myeloablative range from the start of treatment might be effective, and the results reported for the escalated BEACOPP regimen support this idea, although only one comparison of this regimen to ABVD has yet been completed. A second approach is to carry out early response assessment using 2-[fluorine-18]fluoro-2-deoxy-D-glucosepositron emission tomography (FDG-PET), which has been shown in retrospective studies to yield powerful prognostic information when carried out after two cycles of ABVD, to the extent that the FDG-PET result rendered the baseline prognostic characteristics irrelevant [11] . It is unclear whether the intensity of initial therapy before early response assessment is critical to the outcome however or whether subsequent intensification may compensate for less intense initial treatment.
Strategies for improving treatment results have manipulated dosage, including dose intensity and total dose as well as schedule of treatment. Hasenclever's effective dose model, which is derived from the more generalised Skipper model by taking into account heterogeneity in tumour growth and chemosensitivity, predicted that a dose escalation of 30% in chemotherapy within the same treatment duration could result in a 10% increase in PFS [12] . The timing of intensification may be relevant, in that suboptimal initial therapy might allow the development of resistance within a heterogeneous tumour, 
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making it impossible for subsequent intensification to compensate. There is relatively little evidence on this subject. The German Hodgkin Study Group showed in their multicentre studies (HD4-HD9) involving 4626 patients that grade III/IV leukopenia was strongly associated with better freedom from treatment failure [13] , indicating that individuals in whom the treatment had greatest biological effects were likely to derive the most benefit in terms of tumour control, but this is by no means definitive.
The present analysis was undertaken to investigate whether DI in the first two cycles of standard ABVD chemotherapy had an impact upon outcome. The results indicate that this is not the case: there was no evidence of a worse PFS with lower DI in the first two cycles of ABVD, and optimal DI did not appear to result in a lower failure rate. There was some indication that DI over the whole course of treatment might exert an effect, but this did not appear to be more pronounced early in the course. The hypothesis that early DI is critical to outcome is therefore not supported by these data, and further it indicates that later restoration of DI might compensate for suboptimal initial treatment.
This analysis reflects current practice, with implementation of dose reductions and delays according to the original design of the ABVD regimen. The data derive from a large multicentre randomised controlled trial in which patients were managed following a common protocol and for which there is mature follow-up. Data on drug doses were collected prospectively, giving confidence in its accuracy. There are, however, limitations to this analysis. The data have been examined retrospectively rather than in a prospective randomised trial, and this carries the risk of bias, with patients having adverse prognostic factors perhaps receiving a different intensity of therapy. There is some indication that patients with the worst prognostic features were more likely to receive lower initial DI, but this does not appear to have resulted in the low DI group having worse outcomes, a finding supported by the multivariate analysis. The omission of early treatment failures from the analysis is another potential confounding factor, but the small number of patients lost before completion of two cycles makes this unlikely. The principal point of failure for the treatment of HL is recurrence following initial remission, and this outcome measure showed no evidence of a difference according to the initial DI.
In addition to the limitations described above, the relatively narrow range of DI in this analysis does not provide the most rigorous test of the concept of early intensification, and the highest level tested is clearly below that used in the escalated BEACOPP regimen, for example. However, if a dose-response relationship does exist, it should still pertain at the lower ranges of intensity. Since none is apparent at these levels, it seems less likely that it would be seen at higher ones.
The small number of patients in some subgroups necessarily limits the statistical power of the analysis. However, the data on PFS do not show any indication of a worse outcome in the low dose-intensity group if allowance is made for the treatment in later cycles. The limitations of this analysis mean that this study should not be interpreted as supporting reduced DI for the treatment of patients with advanced HL. It should be noted that the use of ABVD is changing, with increasing evidence that the dose reductions specified in this study are too conservative, and Based on 104 PFS events in all 380 patients, timed from start of cycle 3 in patients who had at least two cycles. b Based on 103 PFS events in all 378 patients, timed from start of cycle 3 in patients who had at least two cycles. c Based on 79 PFS events in all 333 patients, timed from the end of cycle 6 in patients who had at least six cycles.
HR, hazard ratio; DI, dose intensity; PFS, progression-free survival; CI, confidence interval.
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Annals of Oncology that in many cases treatment can be given at full dose on schedule despite myelosuppression [14] . It would be helpful to study larger numbers, but ultimately, a prospective randomised trial comparing different initial dose intensities will be needed for resolution of this question. references
